Over the past roughly three years, AstraZeneca PLC’s key oncology drugs, including for lung cancer, have been facing gathering clouds in China.
AZ China President Under Investigation By Chinese Authorities
Cancer Drugs Facing Local Competition
The exact causes leading to Chinese authorities’ investigation of the UK major remain unclear at this point, but its key oncology drugs are facing fierce local competition from homegrown rivals.
More from Legal & IP
• By
Plus deals involving Incyte/Genesis, Merck & Co./Epitopea, Merck Serono/Asceneuron, Tivic Health/Statera and more.
• By
Legal heavyweights from Nishith Desai Associates, Anand and Anand, Corporate Law Group and EY partner and national cyber leader outline key compliance aspects that pharma and their global capability centers may need to factor as India moves to strengthen the framework for the protection of digital personal data.
• By
Novo took the biggest stock price hit of all the drug makers with products subject to Medicare price negotiations in 2027 under the IRA, but at least 11 of its peers on the list will be subject to generic competition between 2025 and 2027.
• By
India cracks down on unethical marketing practices, with AbbVie in the eye of a storm for allegedly violating norms. While the action sends the right signal, a wider clean up including in the devices segment, where things may be “more harmful” may not be easy, say some experts.
More from Immuno-oncology
• By
The MATTERHORN study could set Imfinzi up for another new perioperative use, even though the gastric cancer trial has yet to demonstrate an overall survival benefit.
• By
Summit and Akeso have established a big lead in lung cancer with ivonescimab, but BioNTech aims to make its rival, BNT327, the leader in other tumor types.
• By
The company sees a potential billion-dollar market opportunity in its approved indications and is launching the drug in what an exec called “a very targeted fashion” at a recent conference.